Recent Advances on GABAB Receptor Positive Allosteric Modulators as Potential Pharmacotherapies for Neuropsychiatric Disorders
- 18 September 2024
- book chapter
- Published by Springer Nature
- p. 219-238
Abstract
No abstract availableKeywords
This publication has 85 references indexed in Scilit:
- Effects of GABAB receptor positive allosteric modulator BHF177 and IRS‐1 on apoptosis of hippocampal neurons in rats with refractory epilepsy via the PI3K/Akt pathwayCell Biology International, 2022
- GABAB Receptors and Cognitive Processing in Health and Disease2021
- GABAB Receptors: Anxiety and Mood Disorders2020
- Single‐ and Multiple‐Dose Safety, Tolerability, and Pharmacokinetic Profiles of ASP8062: Results From 2 Phase 1 StudiesClinical Pharmacology in Drug Development, 2020
- Paradoxical effect of baclofen on social behavior in the fragile X syndrome mouse modelBrain and Behavior, 2018
- Effects of GABA-B receptor positive modulator on ketamine-induced psychosis-relevant behaviors and hippocampal electrical activity in freely moving ratsPsychopharmacology, 2017
- KK-92A, a novel GABAB receptor positive allosteric modulator, attenuates nicotine self-administration and cue-induced nicotine seeking in ratsPsychopharmacology, 2017
- GABAA and GABAB receptor dysregulation in superior frontal cortex of subjects with schizophrenia and bipolar disorderSynapse, 2017
- Reduction of excessive alcohol drinking by a novel GABAB receptor positive allosteric modulator ADX71441 in micePsychopharmacology, 2013
- Repeated administration of the GABAB receptor positive modulator BHF177 decreased nicotine self-administration, and acute administration decreased cue-induced reinstatement of nicotine seeking in ratsPsychopharmacology, 2010